Open AccessClinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
Author(s) -
Knorr David A.,
Ni Zhenya,
Hermanson David,
Hexum Melinda K.,
Bendzick Laura,
Cooper Laurence J.N.,
Lee Dean A.,
Kaufman Dan S.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2012-0084
Subject(s) - induced pluripotent stem cell , biology , cytotoxic t cell , embryonic stem cell , embryoid body , adoptive cell transfer , cell therapy , stem cell , antigen , haematopoiesis , immunology , cancer research , cancer immunotherapy , microbiology and biotechnology , immunotherapy , immune system , t cell , in vitro , biochemistry , gene
This study used a two‐stage culture system to efficiently produce natural killer (NK) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in the absence of cell sorting and without need for xenogeneic stromal cells. Although different hESC and iPSC lines had varying efficiencies in hematopoietic development, all cell lines tested could produce functional NK cells. This improved method to develop NK cells from human pluripotent stem cells provides a system for clinical‐scale expansion of antitumor lymphocytes and a genetically amenable platform to study human NK cell development.